Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATN-103 in active rheumatoid arthritis
NCT00959036Phase 2Completed
- Sponsor
- Sanofi
- Start
- Sep 2009
- Primary completion
- Jan 2011
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH)
- Countries
- 9
01
Overview
A Phase 2 trial of ozoralizumab in rheumatoid arthritis (RA), sponsored by Sanofi. Started Sep 2009; status: completed.
02
Drugs
ozoralizumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT00959036.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00959036.